Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | ATM | Q13315 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | EEF2K | O00418 | 16/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242992 | 0.87 | MAPT (0.53) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4051773 | 0.85 | EEF2K (0.54) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4047809 | 0.82 | EEF2K (0.52) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4052747 | 0.82 | KDM4E (0.58) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4051300 | 0.82 | KDM4E (0.71) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4046385 | 0.80 | KDM4E (0.59) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4045460 | 0.80 | KDM4E (0.59) | MAPTKDM4EATMHTTEEF2K | |
| SCHEMBL4047805 | 0.80 | EEF2K (0.50) | MAPTKDM4EATMNPC1HTT | |
| SCHEMBL4053028 | 0.80 | KDM4E (0.72) | MAPTKDM4EATMHTTALDH1A1 | |
| SCHEMBL4054309 | 0.78 | EEF2K (0.72) | MAPTKDM4EHTTEEF2KALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819710-B1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | PNPO, PDE4A, DPYD | MAPT 2618/4885KDM4E 1600/4885ATM 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.